|
Published by: BCC Research
Published: Sep. 1, 2001 - 202 Pages
Table of Contents
Introduction
Study Goal And Objectives
Reasons For Doing The Study
Contributions Of The Study And For Whom
Scope And Format
Methodology
Information Sources
Related Bcc Reports
Bcc On-Line Services
Summary
Overview
Diseases Preventable By Vaccination
A Brief History Of Vaccines
The Immune System
Nonspecific Immunity
Phagocytes
Cytokines
Specific Immunity
Lymphocytes
B-Cells
T-Cells
The Process Of Immunization
Types Of Vaccines
Killed Whole Organism Vaccines
Live Attenuated Microorganism Vaccines
Subunit Vaccines
Genetically Engineered Vaccines
Conjugate Vaccines
Emerging Vaccine Technologies: Dna Vaccines
The Difference Between Dna Vaccines And Recombinant Dna Vaccines
Applications Of Dna Vaccines
Advantages Of Dna Vaccines Over Traditional Vaccines
Disadvantages Of Dna Vaccines Compared To Traditional Vaccines
Adjuvants
New Vector Systems
Next Generation Vaccine Technology
Innovations In Vaccine Delivery Systems
Edible Vaccines
Mucosal Delivery
Intranasal Delivery
Oral Delivery
Injection Without Needles
Transdermal Patch Delivery
New Delivery Systems May Facilitate Storage And Distribution
Trends Driving The Vaccine Market
Trends In Vaccine Marketing
Vaccine Product Introductions In 1998, 1999 And 2000
Prophylactic Vaccine Products
The Market For Prophylactic Vaccines
Pediatric Vaccines
Increasing Rates Of Childhood Immunization
Childhood Immunization Schedule
Available Vaccines
Bcg Vaccine
Diphtheria/Tetanus/Pertussis Vaccines
Hemophilus Influenza Type B Vaccine
Hepatitis A Vaccine
Hepatitis B Vaccine
Measles/Mumps/Rubella Vaccines
Meningococcus Disease Vaccine
Pneumococcal Disease Vaccine
Polio Vaccines
Rotavirus Vaccines
Varicella Vaccine
The Market For Pediatric Vaccines
Pediatric Vaccines In Development
Combination Vaccines
Malaria Vaccine
Meningococcus A, B And C Vaccines
Parainfluenza Virus Type 3 Vaccine
Pneumococcal Disease Vaccines
Respiratory Syncytial Virus Vaccines
Adult Vaccines
Immunization Rates
Adult Vaccines Available In The U.S.
Bcg Vaccine
Cholera Vaccine
Hepatitis A Vaccine
Hepatitis B Vaccines
Combination Hepatitis A/Hepatitis B Vaccine
Influenza Vaccines
Japanese Encephalitis Vaccines
Lyme Disease Vaccine
Meningococcal Vaccines
Pneumococcal Disease Vaccines
Rabies Vaccines
Tetanus/Diphtheria Vaccines
Typhoid Vaccine
Yellow Fever Vaccine
The Market For Adult Vaccines
Adult Vaccines In Development
Cholera Vaccines
Dengue Fever And Japanese Encephalitis Vaccines
Ebola Virus Vaccine
Helicobacter Pylori Vaccines
Hepatitis Vaccines
Hepatitis C
Hepatitis D
Hepatitis E
Herpesvirus Vaccines
Epstein Barr Virus Vaccines
Influenza Vaccines
Staphylococcus Vaccine
Typhoid Fever Vaccine
Therapeutic Vaccine Products
The Market For Therapeutic Vaccine Products
Aids Vaccines
The Expanded Definition Of Aids
Aids Statistics
Hiv Infection And Aids Cases In The U.S.
The Epidemic
Aids Vaccines In Development
National Institute Of Allergy And Infectious Diseases Vaccine Development Partnerships
Results Of Early Trials With Hiv/Aids Vaccines
Aidsvax
Alvac Hiv
Genevax-Hiv Plasmid Dna Vaccine
Gp120 Vaccines
Hgp-30w
Mnrgp120/Hiv-1
Gp160 Vaccines
Rgp160
Vaxsyn
Live Virus Hiv Vaccine
P24 Virus-Like Particle
Remune
Tat Toxoid
Bacteria-Based Vaccines
Cancer Vaccines
Cancer Statistics
Worldwide Cancer Statistics
U.S. Cancer Statistics
Current Methods Of Treatment
Surgery
Radiation Therapy
Pharmaceutical Therapy
Cancer Vaccines: A New Modality Of Care
Antigens: Their Role In Cancer Vaccines
Vaccine Development: Strategies
A Summary Of Two Approaches: Low-Technology Vs. High-Technology
Cancer Vaccines In Development
Cancer Vaccines On The Market
Cancer Vaccines In Development
4b5
Alvac-Cea/B7.1
Autologous Tumor Vaccines
Bec2
Blp25
Ceavac
Colon Cancer Vaccine
Dendritic Cell-Based Vaccines
Human Papilloma Virus Vaccines
Melacine
Novopharm-M1
Ovarex
Prostvac-Vf
Theratope
Triab
Trigem
Gene Therapy Approaches To The Treatment Of Hiv/Aids And Cancer
Why Gene Therapy?
Delivery Of Genes As Drugs
Synthetic Vectors And Viral Vectors
Gene Expression Systems
Therapeutic Vaccines Against Other Diseases
Addiction Vaccines
Allergy Vaccines
Alzheimer's Disease
International Aspects
The European Vaccines Market
Efforts To Increase Vaccination Worldwide
Collaborations To Develop Aids Vaccines In India
Industry Structure
Market Leaders
Phases Of Vaccine Trials
Safety Concerns
Company Profiles
Antex Biologics Inc.
Business Overview
Financial Information
Leading Products
Corporate Strategy
Avax Technologies, Inc.
Business Overview
Financial Information
Leading Products
Corporate Strategy
Aventis
Business Overview
Financial Information
Leading Products
Corporate Strategy
Aviron Corporation
Business Overview
Financial Information
Leading Products
Corporate Strategy
Baxter International Inc.
Business Overview
Financial Information
Leading Vaccine Products
Corporate Strategy
Biomira Inc.
Business Overview
Financial Information
Leading Products
Corporate Strategy
Chiron Corporation
Business Overview
Financial Information
Leading Products
Corporate Strategy
Corixa Corporation
Business Overview
Financial Information
Products In Development
Corporate Strategy
Glaxosmithkline Plc
Business Overview
Financial Information
Leading Products
Corporate Strategy
Imclone Systems, Inc.
Business Overview
Financial Information
Leading Products
Corporate Strategy
The Immune Response Corporation
Business Overview
Fnancial Information
Leading Products
Corporate Strategy
Medimmune, Inc.
Business Overview
Financial Information
Leading Products
Corporate Strategy
Merck & Company, Inc.
Business Overview
Financial Information
Leading Vaccine Products
Corporate Strategy
North American Vaccine Inc. (See Baxter International)
Progenics Pharmaceuticals, Inc.
Business Overview
Financial Information
Leading Products
Corporate Strategy
Company Names And Addresses
List Of Tables
Summary Table:
The Market For Prophylactic And Therapeutic Vaccines: Worldwide Sales, Through 2006
1 Worldwide Incidence/Prevalance Of Selected Diseases Amenable To Prophylactic Or Therapeutic Immunization
2 Licensed Vaccines Available In The U.S., 2000
3 Selected Licensed Vaccines Available In The U.S. By Type
4 The Market For Prophylactic Vaccines: Worldwide Sales, Through 2006
5 Pediatric Vaccines Licensed In The U.S., 2001
6 Recommended Childhood Immunization Schedule, 2000
7 The Market For Pediatric Vaccines: Worldwide Sales, Through 2006
8 The Market For Pediatric Vaccines: U.S. Sales, Through 2006
9 The Market For Dtp And Dtap Vaccines: Worldwide Sales, Through 2006
10 The Market For Dtp And Dtap Vaccines: U.S. Sales, Through 2006
11 The Market For Pediatric Hemophilus Influenzae Vaccines: Worldwide Sales, Through 2006
12 The Market For Pediatric Hemophilus Influenzae Vaccines: U.S. Sales, Through 2006
13 The Market For Pediatric Hepatitis Vaccines: Worldwide Sales, Through 2006
14 The Market For Pediatric Hepatitis Vaccines: U.S. Sales, Through 2006
15 The Market For Measles/Mumps/Rubella Vaccines: Worldwide Sales, Through 2006
16 The Market For Measles/Mumps/Rubella Vaccines: U.S. Sales, Through 2006
17 The Market For Pediatric Pneumococcal Vaccines: Worldwide Sales, Through 2006
18 The Market For Pediatric Pneumococcal Vaccines: U.S. Sales, Through 2006
19 The Market For Poliovirus Vaccines: Worldwide Sales, Through 2006
20 The Market For Poliovirus Vaccines: U.S. Sales, Through 2006
21 The Market For Varicella Vaccine: Worldwide Sales, Through 2006
22 The Market For Varicella Vaccine: U.S. Sales, Through 2006
23 Selected Prophylactic Pediatric Vaccines In Phase Ii Or Later Development, 2001
24 Routine Immunization Recommendations For Adults
25 Recommended Immunizations For Adults
26 Adult Vaccines Licensed In The U.S., 2001
27 The Market For Adult Vaccines: Worldwide Sales, Through 2006
28 The Market For Adult Vaccines: U.S. Sales, Through 2006
29 The Market For Adult Hepatitis A Vaccines: Worldwide Sales, Through 2006
30 The Market For Adult Hepatitis A Vaccines: U.S. Sales, Through 2006
31 The Market For Adult Hepatitis B Vaccines: Worldwide Sales, Through 2006
32 The Market For Adult Hepatitis B Vaccines: U.S. Sales, Through 2006
33 The Market For Influenza Vaccines: Worldwide Sales, Through 2006
34 The Market For Influenza Vaccines: U.S. Sales, Through 2006
35 The Market For Lyme Disease Vaccine: Worldwide Sales, Through 2006
36 The Market For Lyme Disease Vaccine: U.S. Sales, Through 2006
37 The Market For Meningococcal Vaccines: Worldwide Sales, Through 2006
38 The Market For Pneumococcal Vaccines: Worldwide Sales, Through 2006
39 The Market For Pneumococcal Vaccines: U.S. Sales, Through 2006
40 The Market For Rabies Vaccines: Worldwide Sales, Through 2006
41 The Market For Rabies Vaccines: U.S. Sales, Through 2006
42 The Market For Tetanus, Tetanus/Diphtheria And Other Vaccines: Worldwide Sales, Through 2006
43 The Market For Tetanus, Tetanus/Diphtheria And Other Vaccines: U.S. Sales, 2000-2006
44 Selected Prophylactic Adult Vaccines In Development, 2001
45 The Market For Therapeutic Vaccines: Worldwide Sales, Through 2006
46 The Market For Therapeutic Vaccines: U.S. Sales, Through 2006
47 Selected Hiv And Aids Vaccines In Development
48 Worldwide Incidence And Mortality Of Cancer: 2000
49 Cancer Deaths Per 100,000 Population In Selected Countries, 1994-1997
50 Incidence, Mortality And Survival Rates For Common Cancers: U.S., 2000
51 Cancer Prevalence Rates: U.S., 2000
52 Therapeutic Cancer Vaccine Products In Development
53 Selected Gene Therapy Clinical Trials Currently Underway
54 Selected Gene Therapies In Development For Hiv/Aids
55 Selected Gene Therapies In Development For Cancer
56 Market Share Of Leading Vaccine Manufacturers: 2000
57 Avax's Product Pipeline
58 Vaccines Marketed By Aventis Pasteur, 2000
59 Aviron's Product Pipeline
60 Glaxosmithkline's Branded Product Sales By Therapeutic Class, 1999-2000
61 Imclone Systems' Product Pipeline
62 Immune Response's Product Pipeline
63 Medimmune's Vaccine Product Pipeline
64 Merck's Marketed Leading Vaccine Products
65 Merck's Vaccine Product Pipeline
66 Progenics' Product Pipeline
List Of Figures
Summary Figure:
The Market For Prophylactic And Therapeutic Vaccines: Worldwide Sales, 2000, 2001 And 2006
1 The Market For Prophylactic Vaccines: Worldwide Sales, 2000, 2001 And 2006
2 Percentage Of The World Prophylactic Vaccine Market Held By Combination Products, 2000 And 2006
3 Market Share Of Leading Vaccine Manufacturers: 2000
AbstractNew developments in vaccine technology that have emerged over the past decade have transformed this relatively lackluster, price-competitive market sector into a technology-driven industry characterized by increasing annual growth rates that approached 10% during the late 1990s. Prophylactic vaccines for children and adults have been the mainstay of this market and although dramatic innovations in these preventive products are not anticipated, this category will enjoy continued modest growth. A tidal wave of growth in the vaccines market is expected with the introduction of therapeutic vaccines currently in development to treat acquired-immune deficiency syndrome (AIDS), cancer and other major diseases. DNA-and protein-based therapeutic vaccines that boost the immune response to cancerous cells will add a powerful new component to standard treatments for cancer. The first cancer vaccine is projected to enter the market in 2002. Recent product introduction and products projected for introduction during the forecast period (2001 to 2006) are discussed in this report, with sales projections provided. Traditional vaccines as well as those incorporating antibodies, growth factors, cytokines, hormones and recombinant proteins and peptides are assessed. Regulatory trends, such as significant changes in vaccination programs recommended in 1999 by the Centers for Disease Control and Prevention (CDC), are discussed and their affect on the market is analyzed. In addition to analyses of leading competitors in the current worldwide vaccines market, this report assesses companies poised to introduce products during the forecast period and how this will change the face of the competitive environment.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
